🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT05756296
Starting soon Observational

The Long-term Consequences of Neonatal Encephalopathy in the Hypothermia Era

NCT05756296 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2023-11-01
Last updated
2023-10-23

Condition(s) studied

Neonatal EncephalopathyTherapeutic HypothermiaBrain InjuriesChild Development

Investigational drug(s) / intervention(s)

Therapeutic hypothermia

Therapeutic hypothermia: whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed for moderate or severe NE

Study summary

The goal of this study is to characterize the ability and related brain profiles of children with Neonatal encephalopathy (NE) - Therapeutic hypothermia (TH) at 9 years old. The main questions it aims to answer are:

1. Compare executive function, attention, social cognition, behaviour, anxiety, self-esteem, and peer problems between children with NE-TH and matched peers without NE.
2. Compare brain volumes, cortical and subcortical morphology, white matter microstructure, and myelination between children with NE-TH and matched peers without NE.
3. Evaluate the associations of perinatal risk factors and structural brain integrity with neuropsychological deficits to inform about the potential aggravating and protective factors for neuropsychological functioning.

Participants will complete one study visit to perform standardized evaluations and a brain MRI. Parents of participants will be invited to complete a series of questionnaires during this study visit or at a moment of their choice virtually.

Eligibility

Sex
ALL
Min age
8 Years
Max age
11 Years
Healthy volunteers
No
Inclusion Criteria: * born between 2014 and 2018 * received whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed received TH for moderate or severe NE Exclusion Criteria: Participants with a history of * congenital infections * genetic or metabolic disorders * major brain malformations (e.g., lissencephaly) and * any contraindication for MRI (e.g., metal implant, claustrophobia)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Centre Hospitalier Universitaire Ste-Justine (CHUSJ). Montreal Quebec
the Montreal Children's Hospital (MCH) of the McGill University Health Centre Montreal Quebec

More McGill University Health Centre/Research Institute of the McGill University Health Centre trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05756296 on ClinicalTrials.gov ↗ ← All trials in Canada